Trials / Recruiting
RecruitingNCT06733051
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
A Single-arm, Open-label, Phase II Study of Golidocitinib and Benmelstobart Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (ENKTL) (JACKPOT50)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Golidocitinib | 150 mg, administered once daily from Day 1 to Day 21 (D1-D21) |
| DRUG | Benmelstobart | 1200 mg, administered on Day 1 (D1) of every cycle |
Timeline
- Start date
- 2024-01-27
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2024-12-13
- Last updated
- 2025-02-10
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06733051. Inclusion in this directory is not an endorsement.